Catalytic Activity of Nonaggregating Cu Nanoparticles Supported in Pores of Zeolite for Aerobic Oxidation of Benzyl Alcohol.

Cu nanoparticles (NPs) as catalysts have the good advantage of being more abundant than noble metal NPs. In this study, we synthesized nonaggregating Cu NPs supported in Y-type zeolite by the photoreduction method. In this method, Cu ions in pores of zeolite can be slowly reduced with a small amount of reductant at room temperature. The high-resolution transmission electron microscope, energy dispersive X-ray spectroscopy, X-ray diffraction patterns, and UV-Vis spectra supported that nonaggregating Cu NPs existed in the pores of zeolite. Catalytic activities of Cu NP-zeolite were investigated for the aerobic oxidation of benzyl alcohol. Our Cu NP-zeolite had a large turnover frequency of 17 h-1. The yield of benzaldehyde increased in proportion to the amount of Cu loading at ≤0.5 wt %, indicating that Cu NPs in pores of zeolite work as catalysts for selective aerobic oxidation of benzyl alcohol. The high catalytic activity was brought by nonaggregating Cu NPs in pores of zeolite. The catalytic reaction for other aromatic alcohols with electron-donating groups proceeded, whereas it did not proceed for the aromatic alcohols with electron-withdrawing groups or aliphatic alcohols, indicating that the interaction between zeolite and the benzene ring also contributed to the reaction. This study would be expected to contribute to the development of Cu NP catalysts.

Diversity in Cancer Care: Current Challenges and Potential Solutions to Achieving Equity in Clinical Trial Participation.

ABSTRACT: Access to and participation in cancer clinical trials determine whether such data are applicable, feasible, and generalizable among populations. The lack of inclusion of low-income and marginalized populations limits generalizability of the critical data guiding novel therapeutics and interventions used globally. Such lack of cancer clinical trial equity is troubling, considering that the populations frequently excluded from these trials are those with disproportionately higher cancer morbidity and mortality rates. There is an urgency to increase representation of marginalized populations to ensure that effective treatments are developed and equitably applied. Efforts to ameliorate these clinical trial inclusion disparities are met with a slew of multifactorial and multilevel challenges. We aim to review these challenges at the patient, clinician, system, and policy levels. We also highlight and propose solutions to inform future efforts to achieve cancer health equity.